checkAd

    Update to 01/26/21 COVI-MSC Press Release  215  0 Kommentare Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells - Seite 3

    Media and Investor Relations

    Contact: Alexis Nahama, DVM (SVP Corporate Development)

    Telephone: 1.858.203.4120

    Email: mediarelations@sorrentotherapeutics.com

    Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB, DAR-T, COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-DROPS, COVI-MSC, COVI-TRACK, COVI-TRACE and COVI-STIX are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc.

    Lesen Sie auch

    ZTlido is a trademark owned by Scilex Pharmaceuticals Inc.

    All other trademarks are the property of their respective owners.

    2021 Sorrento Therapeutics, Inc. All Rights Reserved. 


    Seite 3 von 3


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Update to 01/26/21 COVI-MSC Press Release Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells - Seite 3 Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC starting Monday (January 25, 2021) and discharged last Friday (January 29, 2021) after 3rd COVI-MSC infusionTo date, 4/4 …

    Schreibe Deinen Kommentar

    Disclaimer